Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-Concept Study in Healthy Volunteers.
Latest Information Update: 05 Dec 2022
Price :
$35 *
At a glance
- Drugs Cannabidiol (Primary) ; Insulin (Primary) ; URB 597 (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics; Proof of concept
- Acronyms EICAS
- 12 Aug 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 12 Aug 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2022.
- 12 Aug 2019 Planned initiation date changed from 1 Jun 2019 to 1 Jun 2020.